DIONYSOS study comparing dronedarone with amiodarone

Cook, Gina; Sasich, Larry D.; Sukkari, Sana R.

doi:10.1136/bmj.c285

Cited by 11 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Intolerance of dronedarone was mainly secondary to gastrointestinal side effects (diarrhea, vomiting, and nausea), and was responsible for discontinuation of the drug in only 3.2% of patients in clinical trials, while thyroid and neurological events (tremor and sleep disorder) were mostly responsible for discontinuation of amiodarone 66. Fewer patients in the dronedarone group had a QTc interval >500 milliseconds (10.9% vs 20.5%, respectively).…”

Section: Clinical Trials With Dronedaronementioning

confidence: 99%

Managing atrial fibrillation in the elderly: critical appraisal of dronedarone

Trigo¹,

Fischer²

2011

CIA

View full text Add to dashboard Cite

Atrial fibrillation is the most commonly seen arrhythmia in the geriatric population and is associated with increased cardiovascular morbidity and mortality. Treatment of the elderly with atrial fibrillation remains challenging for physicians, because this unique subpopulation is characterized by multiple comorbidities requiring chronic use of numerous medications, which can potentially lead to severe drug interactions. Furthermore, age-related changes in the cardiovascular system as well as other physiological changes result in altered drug pharmacokinetics. Dronedarone is a new drug recently approved for the treatment of arrhythmias, such as atrial fibrillation and/or atrial flutter. Dronedarone is a benzofuran amiodarone analog which lacks the iodine moiety and contains a methane sulfonyl group that decreases its lipophilicity. These differences in chemical structure are responsible for making dronedarone less toxic than amiodarone which, in turn, results in fewer side effects. Adverse events for dronedarone include gastrointestinal side effects and rash. No dosage adjustments are required for patients with renal impairment. However, the use of dronedarone is contraindicated in the presence of severe hepatic dysfunction.

show abstract

Section: Clinical Trials With Dronedaronementioning

confidence: 99%

Managing atrial fibrillation in the elderly: critical appraisal of dronedarone

Trigo¹,

Fischer²

2011

CIA

View full text Add to dashboard Cite

show abstract

“…Angaben als n (%). VHF = Vorhofflimmernmentiert (HR = 0,80; 95%-KI 0,60-1,07, log-rank p-Wert = 0,13)[4,21]. Obwohl also Amiodaron in der Prävention von Vorhofflimmern effektiver war, zeigte Dronedaron eine deutlich geringere Toxizität auf und rief weniger Unerwünschte Ereignisse hervor.Das neue Antiarrhythmikum Dronedaron wurde in einem umfangreichen Programm von randomisierten klinischen Studien bei Patienten mit Vorhofflimmern geprüft.…”

unclassified

Klinisches Profil des neuen Antiarrhythmikums Dronedaron

Schmitt

Lewalter

Pittrow

et al. 2010

Dtsch med Wochenschr

View full text Add to dashboard Cite

The new antiarrhythmic drug dronedarone (SR 33 589) is a benzofuran derivative structurally similar to amiodarone, however is noniodinated. The additional methansulfonylgroup renders it less lipophilic, with a substantially shorter half-life, compared to the parent compound. The electrophysiological properties of both agents are similar with inhibition of Na+, K+, and Ca++ currents (all Vaughan-Williams classes). The agent has been evaluated in a large clinical study program. The daily dose of dronedarone 800 mg has been shown (DAFNE) to be effective and well tolerated. In two design-identical randomised clinical trials (EURIDIS and ADONIS trial) the efficacy of dronedarone to maintain sinus rhythm in patients with chronic atrial fibrillation/flutter was shown to be clearly superior to placebo. The ERATO study showed the rate control properties of dronedarone. In the ATHENA morbidity/mortality study, the combined endpoint death or hospitalisation due to cardiovascular events occurred significantly less often in the dronedarone group compared to the placebo group. Particularly due to its beneficial effects on clinical outcomes such as cardiovascular hospitalizations and death in the context of high tolerability dronedarone appears to be a promising new antiarrhythmic compound.

show abstract

“…• Dronedarona: es un fármaco de composición similar a amiodarona al que se le ha retirado el yodo y se le ha añadido un radical metilsulfonamida, por lo que se evita su acumulación en el tejido graso a diferencia de amiodarona (43). En cuanto a eficacia es inferior a amiodarona (44). Está contraindicada en pacientes con disfunción ventricular severa o IC avanzada (45).…”

Section: Control Del Ritmo Vs Control De Frecuenciaunclassified

Aplicación de nuevos biomarcadores en el estudio de pacientes con fibrilación auricular persistente

Merino¹,

María²

View full text Add to dashboard Cite

Péptido natriurético vascular COR: Característica operativa del receptor CV: Coeficiente de variación CVE: Cardioversión eléctrica DM: Diabetes mellitus DTDVI: Diámetro telediastólico del ventrículo izquierdo DTSVI: Diámetro telesistólico del ventrículo izquierdo E: Especificidad EPOC: Enfermedad pulmonar obstructiva crónica FA: Fibrilación auricular FC: Frecuencia cardíaca FEVI: Fracción de eyección del ventrículo izquierdo FFAA: Fármacos antiarrítmicos

show abstract

DIONYSOS study comparing dronedarone with amiodarone

Cited by 11 publications

References 1 publication

Managing atrial fibrillation in the elderly: critical appraisal of dronedarone

Managing atrial fibrillation in the elderly: critical appraisal of dronedarone

Klinisches Profil des neuen Antiarrhythmikums Dronedaron

Aplicación de nuevos biomarcadores en el estudio de pacientes con fibrilación auricular persistente

Contact Info

Product

Resources

About